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Abstract
Hepatocellular carcinoma (HCC) is among the most 
common cancer diseases worldwide. Arterial hypervas-
cularisation is an essential step for HCC tumorigenesis 
and can be targeted by transarterial chemoemboliza-
tion (TACE). This interventional method is the standard 
treatment for patients with intermediate stage HCC, 
but is also applied as “bridging” therapy for patients 
awaiting liver transplantation in many centers world-
wide. Usually the devascularization effect induced by 
TACE is transient, consequently resulting in repeated 
cycles of TACE every 4-8 wk. Despite documented sur-
vival benefits, TACE can also induce the up-regulation 
of proangiogenic and growth factors, which might con-
tribute to accelerated progression in patients with in-
complete response. In 2007, sorafenib, a multi-tyrosine 
kinase and angiogenesis inhibitor, was approved as 
the first systemic treatment for advanced stage HCC. 
Other active targeted compounds, either inhibitors 
of angiogenesis and/or growth factors, are currently 
being investigated in numerous clinical trials. To over-
come revascularisation or tumor progression under 
TACE treatment it seems therefore attractive to com-
bine TACE with systemic targeted agents, which might 
theoretically block the effects of proangiogenic and 
growth factors. Over the last 12 mo, several retrospec-
tive or prospective cohort studies combining TACE and 
sorafenib have been published. Nevertheless, robust 
results of the efficacy and tolerability of such combina-
tion strategies as proven by randomized, controlled tri-
als are awaited in the next two years.
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INTRODUCTION
The incidence of hepatocellular carcinoma (HCC) is ris-
ing with a world-wide annual incidence above 600 000
[1]. 
Treatment of HCC is challenging because HCC mainly 
occurs within liver cirrhosis
[1], and therapy options and 
prognosis are determined by tumor biology as well as 
impaired liver function. Several clinical staging systems 
have been proposed
[2]. However, the most commonly 
used in Western countries is the Barcelona Clinic Liver 
Cancer (BCLC) system
[3,4]. According to this algorithm, 
treatment is stratified according to tumor stage, liver func-
tion, and performance status. Intermediate stage HCC 
(BCLC stage B) without options for surgical treatment 
or ablation is treated by transarterial chemoembolization 
(TACE). TACE has been shown to expand median sur-
vival from 16 to 19-20 mo
[5,6]. In patients with advanced 
(BCLC stage C) and especially end-stage HCC (BCLC 
stage D), survival depends not only on progression of 
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tumor disease but depends incremental on accompany-
ing liver dysfunction, also. Without intervention, survival 
of patients with advanced HCC rarely exceeds 6 mo, and 
median survival in patients with end-stage HCC (BCLC 
stage D, Okuda stage Ⅲ, performance status 3-4) is 
commonly below 3-4 mo
[4,7-9]. According to the modified 
BCLC system, the dual kinase inhibitor sorafenib is con-
sidered the standard of care for patients with advanced 
HCC
[10]. However, the survival benefit is limited to ap-
proximately 3 mo, whereas disease stabilization can be 
achieved in 27%-78% as shown in prospective trials
[11-14].
Typically, HCC is a hypervascularized tumor with 
characteristic early arterial enhancement during dynamic 
imaging, which is the rational for TACE. By TACE, 
however, mainly central vessels of a tumor nodule are 
occluded, while progression may occur via neovascular-
ization in the tumor periphery. In theory, this might be 
prevented or at least attenuated by concomitant systemic 
treatment with anti-angiogenic agents (Figure 1).
ANGIOGENESIS IN PATHOGENESIS OF 
HEPATOCELLULAR CARCINOMA
Chronic hepatitis and hepatic fibrogenesis are closely 
connected to angiogenesis
[15]. Different cytokines, growth 
factors, and metalloproteinases are involved in these pro-
cesses. Vascular endothelial growth factor (VEGF) was 
shown to be crucially involved in angiogenesis as well as 
fibrogenesis
[15]. Despite other factors, hepatic tissue hy-
poxia seems to be a relevant trigger for angiogenesis in 
necroinflammatory liver disease, especially by induction 
of VEGF, resulting in increasing arterial contribution 
to hepatic perfusion
[16,17]. At this stage, the majority of 
neo-vessels originate from the portal vein, supporting 
short-circuits between the portal vein system and the he-
patic veins
[16,18]. Despite the predominant occurrence of 
HCC in liver cirrhosis rather than in non-cirrhotic liver 
disease
[1], it is still unknown whether HCC arises from 
hepatic stem cells or from hepatocytes via malignant 
transformation. The latter concept is supported by the 
observation that development of HCC from dysplastic 
nodules has been described
[19,20]. Arterial hypervascu-
larization seems to be pathognomonic for established 
HCC, and HCC nodules larger than 2 cm regularly show 
arterial enhancement
[21,22]. Therefore, neovascularization 
seems to be crucial for HCC tumorigenesis.
Consistently, increased expression of angiopoietin-1/-2 
mRNA in tumor tissue was reported, suggesting a criti-
cal role of neo-vascularisation for HCC pathogenesis
[23]. 
Moreover, augmented expression of VEGF was found 
in HCC, and higher serum VEGF levels were associated 
with poor prognosis of patients with HCC
[24-29]. In con-
trast, a recent study showed that neither VEGF-A nor 
VEGFR were up-regulated in HCC tissue, and angio-
tensin-1/-2 expression were only modestly changed
[30]. 
Of note, sinusoidal capillarization suggesting vascular 
remodeling was observed within the same study
[30]. 
These inconsistent data further highlight that tumor an-
giogenesis is a complex process and most likely hetero-
geneous. The angiopoietin/VEGF system seems to play 
an important role in angiogenesis of HCC, but other, yet 
incompletely understood pathways may also be involved. 
THERAPEUTIC INHIBITION OF ANGIO-
GENESIS IN HEPATOCELLULAR CARCI-
NOMA
Inhibition of angiogenesis is an established and success-
ful treatment strategy in a variety of malignant diseases. 
The liver is predominantly supplied by the portal venous 
system, whereas HCC nodules are characterized by typi-
cal arterial hypervascularization. This accounts for the 
rationale for use of hypervascularization as a diagnostic 
criterion as well as development of angiogenesis inhi-
bition treatment strategies. In the absence of targeted 
agents, embolization of arterial tumor vessels was es-
tablished in the 1980s. Currently, TACE is commonly 
used in patients with HCC BCLC stage 0/A as bridging 
therapy until liver transplantation and as non-curative 
therapy in patients with HCC BCLC stage B and C
[6].
Indeed, TACE may lead to reduction of tumor vas-
cularization and viable tumor volume
[6]. Recently, this 
has also been confirmed for a modified TACE technique 
using doxorubicin eluting beads (DEB)
[31]. Furthermore, 
VEGF levels as a surrogate marker for angiogenesis 
were shown to correlate with therapeutic outcome after 
TACE. Pretreatment VEGF levels were significantly 
higher in patients not responding to TACE compared to 
patients with disease stabilization. Moreover, pretreat-
ment VEGF serum levels > 240 pg/mL were an inde-
pendent prognostic factor for survival
[32].
It has been suggested that tumor progression after 
TACE may be caused by activation of angiogenesis due 
to TACE-induced hypoxemia
[33]. Plasma VEGF levels 
were shown to increase shortly after TACE, reaching 
a peak value one day after TACE
[34-37]. Additionally, in-
crease of plasma VEGF levels after TACE was corre-
lated with the development of metastasis and a reduced 
progression free survival
[35,37]. Unfortunately, reliable bio-
markers predicting response to TACE are missing. Nev-
ertheless, a median survival of 35 mo has been reported 
in patients with complete tumor response
[38]. In this 
study low VEGF levels were associated with a longer 
survival, while higher VEGF levels were detectable in 
patients without tumor response. Of note, prior TACE 
was reported to induce angiogenesis in surgical speci-
mens, whereas patients who underwent surgery with-
out prior TACE had no induction of angiogenesis
[39]. 
Whether the use of DEB-TACE, which can induce 
higher rates of tumor response, also leads to upregula-
tion of proangiogenic factors is under debate
[40,41].
Sorafenib, the first systemically agent approved for 
HCC, is a multikinase inhibitor with activity against 
VEGFR2, PDGFR, c-Kit receptors, b-RAF, and p38
[42], 
signal transduction pathways which seem to be involved 
in pathogenesis of HCC
[43]. However, there are limita-
3076 July 14, 2011|Volume 17|Issue 26| WJG|www.wjgnet.comtions on the therapy with sorafenib, founded on re-
stricted efficacy and potential side effects, mainly fatigue, 
diarrhea and hand-food syndrome. In comparison to 
TACE valid predictive biomarkers are missing, also
[11].
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Table 1  Efficacy of systemic targeted monotherapy in hepatocellular carcinoma according to current phase Ⅰ-Ⅲ studies
Author Year Phase Investigational drug n RR DS  PFS/TTP  PFS-6m OS 
O'Neil et al
[59]1 2009 Ⅱ AZD 6244 16   0    37.5 NR NR NR
Malka et al
[60] 2007 Ⅱ Bevacizumab 30    12.5 54 3.5/NR 17 NR
Schwartz et al
[61] 2006 Ⅱ Bevacizumab 30      6.7 57   NR/6.4 NR NR
Siegel et al
[58] 2008 Ⅱ Bevacizumab 46 13 NR 6.9/NR NR    12.4
Raoul et al
[62] 2009 Ⅱ Brivanib 55 11 10   NR/2.8 NR 10
Gruenwald et al
[63] 2007 Ⅱ Cetuximab 27   0 44  2.0/1.9    22.2 NR
Zhu et al
[64] 2007 Ⅱ Cetuximab 30   0 17 1.4/NR NR      9.6
Philip et al
[65] 2005 Ⅱ Erlotinib 38   9 50 3.2/NR 32 13
Thomas et al
[66] 2007 Ⅱ Erlotinib 40   0 43 3.1/NR NR 6.25 (10.75)
2
Blaszkowsky et al
[67] 2010 Ⅲ Everolimus 25   4 44  3.8/3.9       8%      8.4
O’Dwyer et al
[68] 2006 Ⅱ Gefitinib 31   3    22.5 2.8/NR NR      6.5
Lin et al
[69] 2008 Ⅱ Imatinib 15   0    13.3  NR/NR NR NR
Ramanathan et al
[70] 2006 Ⅱ Lapatinib 37   5 35 2.3/NR      2.3      6.2
Rizell et al
[71] 2008 Ⅱ Sirolimus 21      4.8    23.8  NR/NR NR      6.5
Abou-Alfa et al
[12] 2006 Ⅱ Sorafenib 137      2.2    33.6   NR/4.2 NR      9.2
Cheng et al
[72] 2009 Ⅲ Sorafenib 226 (150 treated)      3.3 54   NR/2.8 NR      6.5
Furuse et al
[13] 2008 Ⅰ Sorafenib 27   4 83   NR/4.9    46.2    15.6
Llovet et al
[11] 2008 Ⅲ Sorafenib 602 (299 treated)    2 71   NR/5.5 NR    10.7
Yau et al
[14] 2009 Ⅱ Sorafenib 51   8 18 3.0/NR NR   5
Zhu et al
[73] 2009 Ⅱ Sunitinib 34      2.9 47  3.9/4.1 NR      9.8
Faivre et al
[74] 2009 Ⅱ Sunitinib 37      2.7 35  3.7/5.3 NR   8
Hoda et al
[75] 2008 Ⅱ Sunitinib 23   6 35 NR/NR NR NR
Koeberle et al
[54] 2010 Ⅱ Sunitinib 45   2 40 2.8/2.8 NR      9.3
Kanai et al
[57] 2010 Ⅰ/Ⅱ TSU-68 35      8.6    42.8 NR/2.1 NR    13.1
1Trial stopped; 
2Recorded from therapy start (recorded from diagnosis). DS: Disease stabilization (%);  NR: Not reported; OS: Overall survival (mo); PFS/TTP: 
Progression free survival/time to progression (mo); PFS-6m: Progression free survival rate at 6 mo (%); RR: Response rate [complete + partial response (%)].
A T1
T2
B T1
T2
Figure 1  Dynamic gadolinium-enhanced magnetic resonance imaging (MRI; T1, T2 weighting), in a 67 year old patient with hepatocellular carcinoma 
evolved from liver cirrhosis due to hemochromatosis (A) before initiation of anti-angiogenic therapy and (B) after 70 d or three cycles of transarterial che-
moembolization and continuous administration of sorafenib, respectively. Patient showed partial response according to RECIST criteria. Serum alfa-fetoprotein 
level decreased from 276 to 115 ng/mL.
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TACE AND TARGETED AGENTS IN HCC
Combination of local and systemic inhibition of an-
giogenesis seems to be a consequential step to improve 
outcome in intermediate and advanced stage HCC
[44]. 
Tolerability of combination therapy with sorafenib and 
conventional TACE as well as DEB-TACE was shown 
within different trials
[45-49]. Currently, the combination 
of conventional TACE and sorafenib as well as combi-
nation of sorafenib and DEB-TACE (SPACE trial) is 
being evaluated in phase Ⅱ and Ⅲ trials
[50]. Moreover, 
sorafenib was combined with selective internal radia-
tion therapy within a multicenter phase Ⅱ study show-
ing good efficacy in patients with advanced HCC but 
without extra-hepatic metastasis
[45]. So far, no increased 
toxicity has been reported. The combination of brivanib, 
a dual VEGFR and fibroblast growth factor inhibitor
[51], 
and TACE is currently evaluated within the multicenter 
phase Ⅲ BRISK TA Study.
Another interesting approach could be the inhibition 
of VEGF driven angiogenesis by targeting VEGF with 
siRNA as shown in a proof-of-concept study recently
[52]. 
Furthermore, promising results were reported for other 
agents alone or in combination with TACE, e.g. tega-
fur/uracil, the multi-tyrosine kinase inhibitor TSU-68, 
sunitinib, erlotinib, and the VEGF antibody bevaci-
zumab
[53-57]. However, none of these agents is approved 
for HCC. Of these, bevacizumab is the currently most 
commonly clinical used VEGF inhibitor in a variety of 
malignant entities. However, despite encouraging results 
in earlier trials, even as single agent treatment, bleeding 
complications were reported in up to 11% of patients 
treated with bevacizumab
[58]. For the combination of 
bevacizumab with TACE, severe bleeding and septic 
complications have been reported in 25% of patients, 
and the AVATACE-1 trial investigating TACE in com-
bination with bevacizumab has been terminated due to 
safety concerns in the treatment arm, which does not 
justify a further clinical development of bevacizumab in 
this indication. This highlights that large phase Ⅲ trials 
are required for new agents in HCC, which seems chal-
lenging given the increasing number of phase Ⅰ and Ⅱ 
studies addressing HCC in the last years (Tables 1-3). 
In summary, inhibition of angiogenesis in HCC 
seems a very promising approach for future treatment 
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Table 2  Efficacy of combination therapy with systemic acting agents and targeted therapy in hepatocellular carcinoma according to 
current phase Ⅰ-Ⅱ studies
Author Year Phase Investigational drug n RR DS PFS/TTP  PFS-6m (%) OS 
Sun et al
[76] 2007 Ⅱ Bevacizumab/CapOx 30 11 78   4.5/NR 40 NR
Thomas et al
[55] 2009 Ⅱ Bevacizumab/erlotinib 40 25    42.5   9.0/NR NR 15.7
Hsu et al
[77]  2008 Ⅱ Bevacizumab/capecitabine 45   9 42   4.1/NR NR 10.7
Zhu et al
[78] 2006 Ⅱ Bevacizumab/GemOX 33 20 27   5.3/NR NR   9.6
Berlin et al
[79] 2008 Ⅱ Bortezomib/doxorubicin 39 2.3    25.6   2.4/NR NR   5.7
Asnacios et al
[80]1 2008 Ⅱ Cetuximab/GemOx 45 20 40   4.7/NR NR   9.5
Louafi et al
[81]1 2007 Ⅱ Cetuximab/GemOx 35 24      4.5    NR/NR 40   9.2
Knox et al
[82]2 2008 Ⅱ  G3139/doxorubicin 17   0 35     NR/1.8    17.2   5.4
Abou-Alfa et al
[83]3 2010 Ⅱ Sorafenib/doxorubicin 96   4 77    6.9/8.6      2.7 13.7
Richly et al
[84] 2009 Ⅰ Sorafenib/doxorubicin 18     6.3 69 4.0
4/NR NR NR
1Overlap of patient cohorts cannot be excluded from information provided in the abstracts; 
2Trial stopped due to lack of efficacy; 
3Trial stopped due to supe-
riority of sorafenib; 
4Calculated from a median duration of disease control rate (combined endpoint for complete and partial response as well as stable dis-
ease) of 17.4 wk. CapOx: Capecitabine and oxaliplatin; DS: Disease stabilization (%); GemOx: Gemcitabine and oxaliplatin; NR: Not reported; OS: Overall 
survival (mo); PFS/TTP: Progression free survival/time to progression (mo); PFS-6m: Progression free survival rate at 6 mo (%); RR: Response rate  [complete 
+ partial response (%)].
Table 3  Efficacy of sorafenib and transarterial chemoembolization in hepatocellular carcinoma (sequential therapy not included) ac-
cording to current phase Ⅰ-Ⅱ studies
Author Year Phase Investigational drug n RR DS PFS/TTP OS
Chow et al
[45] 2010 Ⅱ Sorafenib + SIRT 35 31.4   77.1 NR/NR 10.8
Chung et al
[47]1 2010 Ⅱ Sorafenib + TACE 50 NR
2 96 NR/NR NR
Dufour et al
[48] 2010 Ⅰ Sorafenib + TACE 14 NR
3 NR
3 NR
3 NR
3
Erhardt et al
[46]1 2009 Ⅱ Sorafenib + TACE 44 NR
4   63.6   8.0/16.1 11.7
Reyes et al
[49]1 2009 Ⅱ Sorafenib + DEB-TACE 50 NR
5 NR NR/NR NR
1Interim analysis; 
220/50 patients received 2 cycles of transarterial chemoembolization (TACE), only, and 18 of these 20 patients achieved complete response 
compared to 2 patients with progressive disease. 30/50 patients received more than 2 cycles of TACE and achieved partial response or stable disease; 
3Primary 
objective of this prospective trial was evaluation of safety and tolerability of a continuous regimen of sorafenib combined with TACE; 
4According to 31 pa-
tients who received at least 1 cycle of TACE, 2/31 (6.5%) showed complete response, 15/31 (48.4%) showed partial response, and 11/31 (35.5%) showed stable 
disease. PFS, TTP, and OS are given for all 44 patients enrolled at time point of interim analysis; 
5Patients who completed DEB-TACE showed 100% objective 
tumor response and 100% partial response or stable disease according to EASL or RECIST criteria, respectively. DEB-TACE: (Drug eluting beads)-transarterial 
chemoembolization; NR: Not reported; DS: Disease stabilization (%); OS: Overall survival (mo); PFS/TTP: Progression free survival/time to progression (mo); 
PFS-6m: Progression free survival rate at 6 mo (%); RR: Response rate [complete + partial response (%)]; SIRT: Selective internal radio therapy. 
Welker MW et al. Anti-angiogenesis in HCCof HCC. Multimodal approaches with combination of 
local and systemic therapy may further improve survival 
in intermediate and advanced stage HCC. 
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